Beigene, LTD Form 4 insider transactions

Chan Henry Lee, SVP, General Counsel of BeiGene, Ltd., sold 2,666 shares of common stock on August 11, 2026 for $360.00 per share.

John Oyler, Chief Executive Officer and a Director of BeiGene, Ltd., sold 240,810 shares of common stock on August 10, 2026.

Chan Henry Lee, SVP, General Counsel of BeiGene, Ltd., sold 1,044 shares of common stock on July 30, 2026 for $323.69 per share.

Chan Henry Lee, SVP, General Counsel of BeiGene, Ltd., sold 1,669 shares of common stock on July 22, 2026 for $325.00 per share.

John Oyler, Chief Executive Officer and a Director of BeiGene, Ltd., sold 109,713 shares of common stock on July 20, 2026.

John Oyler, Chief Executive Officer and a Director of BeiGene, Ltd., sold 64,628 shares of common stock on July 17, 2026.

John Oyler, Chief Executive Officer and a Director of BeiGene, Ltd., sold 283,154 shares of common stock on July 15, 2026.

John Oyler, Chief Executive Officer and a Director of BeiGene, Ltd., sold 145,861 shares of common stock on July 14, 2026.

John Oyler, Chief Executive Officer and a Director of BeiGene, Ltd., sold 60,218 shares of common stock on July 10, 2026.

BeOne Medicines Ltd. executive Chan Henry Lee reported transactions involving American Depositary Shares and stock options on July 8, 2026, under a Rule 10b5-1 trading plan.

BeOne Medicines President and COO Wu Xiaobin sold 1,292 American Depositary Shares for $276.2592 each to cover mandatory tax withholding obligations.

BeOne Medicines CEO John Oyler reported transactions involving the sale of American Depositary Shares (ADS) due to mandatory tax withholding upon vesting of restricted share units.

Lai Wang, President of Global Head of R&D at BeOne Medicines Ltd., reported transactions involving ordinary shares and American Depositary Shares.

BeOne Medicines President and COO Wu Xiaobin sold 1,357 American Depositary Shares for $266.76 on June 16, 2026, as part of a mandatory tax withholding related to restricted share unit awards.

BeOne Medicines CEO John Oyler reported the sale of American Depositary Shares (ADS) due to mandatory tax withholding related to restricted stock unit awards.

BeOne Medicines SVP, General Counsel Henry Lee sold 590 American Depositary Shares due to mandatory tax withholding upon vesting of restricted share units.

BeOne Medicines Ltd. reports a Form 4 filing detailing a transaction by President, Global Head of R&D, Lai Wang, involving the sale of American Depositary Shares to cover mandatory tax withholding obligations.

Principal Accounting Officer Titus B. Ball reported the acquisition of restricted share units and the sale of American Depositary Shares for tax withholding purposes.

President and Global Head of R&D Lai Wang reported new equity grants and a mandatory tax-related share sale.

CFO Aaron Rosenberg acquired restricted share units and options while selling shares to cover tax obligations.

President and COO Wu Xiaobin reported the acquisition of restricted share units and stock options alongside a mandatory tax-related share sale.

SVP and General Counsel Henry Lee Chan acquired restricted share units and stock options while selling shares to cover tax obligations.

CEO John Oyler acquired restricted share units and stock options while selling shares to cover tax obligations.

Director and Scientific Advisory Board Chair Wang Xiaodong was granted 99,892 restricted share units and 193,492 stock options.

Director Olivier Brandicourt acquired 18,980 restricted share units in BeOne Medicines Ltd. as part of director compensation.

Director Anthony C. Hooper acquired 18,980 restricted share units in BeOne Medicines Ltd. as part of director compensation.

Director Elizabeth Mooney acquired 18,980 restricted share units in BeOne Medicines Ltd. as part of director compensation.

Director Margaret Dugan was granted 18,980 restricted share units in BeOne Medicines Ltd. as part of director compensation.

Director Charles Sawyers acquired 18,980 restricted share units in BeOne Medicines Ltd. as part of director compensation.

Director Shalini Sharp acquired 18,980 ordinary shares of BeOne Medicines Ltd. via restricted share units.